Astrazeneca has withdrawn the authorization of the anti-Covid vaccine in Europe. The newspaper La Verità launched the indiscretion: “In almost general silence, the pharmaceutical company requested and obtained the revocation of the authorization to market the vaccine called Vaxzevria. He submitted his application on 5 March 2024 and the European Commission granted the revocation on 27 March.”we read in the newspaper.
This news led the Anglo-Swedish company to provide some clarifications. “Considering the quantity of available and effective vaccines for the new variants of Covid-19, there was no longer any question for the Vaxzevria vaccine which consequently was no longer produced or distributed. Therefore not foreseeing future demand” for the product, “AstraZeneca has therefore decided to withdraw the marketing authorization for Vaxzevria within the EU”. These clarifications, released to Adnkronos, arise in light of suspicious of the last days.
The decision to withdraw the vaccine, in fact, emerged a few days after shock admissions of Astrazeneca itself, which confessed for the first time in court that its serum can cause “in very rare cases” a side effect known as Thrombosis with Thrombocytopenia Syndrome, thrombosis syndrome with thrombocytopenia (Tts). This is what we read on Telegraph which cites a legal document filed in the British High Court by AstraZeneca last February. Tts can cause blood clots and low platelet counts. AstraZeneca has been sued in a class action lawsuit alleging that its vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases.
In light of the suspicions following this confession, the company was keen to clarify the reasons for withdrawing the vaccine. That is, according to them, low demand. In any case, from now on the vaccine will no longer be authorized in Europe.
Continue reading on StrettoWeb
